GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » ROIC %
中文

AngioDynamics (AngioDynamics) ROIC % : -15.74% (As of Feb. 2024)


View and export this data going back to 2004. Start your Free Trial

What is AngioDynamics ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. AngioDynamics's annualized return on invested capital (ROIC %) for the quarter that ended in Feb. 2024 was -15.74%.

As of today (2024-04-25), AngioDynamics's WACC % is 6.48%. AngioDynamics's ROIC % is -8.09% (calculated using TTM income statement data). AngioDynamics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


AngioDynamics ROIC % Historical Data

The historical data trend for AngioDynamics's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics ROIC % Chart

AngioDynamics Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.14 -2.68 -2.75 -3.51 -4.08

AngioDynamics Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.54 -2.18 -12.69 -16.29 -15.74

Competitive Comparison of AngioDynamics's ROIC %

For the Medical Instruments & Supplies subindustry, AngioDynamics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AngioDynamics's ROIC % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's ROIC % distribution charts can be found below:

* The bar in red indicates where AngioDynamics's ROIC % falls into.



AngioDynamics ROIC % Calculation

AngioDynamics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in May. 2023 is calculated as:

ROIC % (A: May. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: May. 2022 ) + Invested Capital (A: May. 2023 ))/ count )
=-18.679 * ( 1 - 3.66% )/( (461.096 + 421.217)/ 2 )
=-17.9953486/441.1565
=-4.08 %

where

AngioDynamics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Feb. 2024 is calculated as:

ROIC % (Q: Feb. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2023 ) + Invested Capital (Q: Feb. 2024 ))/ count )
=-46.392 * ( 1 - 6.01% )/( (372.457 + 181.592)/ 2 )
=-43.6038408/277.0245
=-15.74 %

where

Note: The Operating Income data used here is four times the quarterly (Feb. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AngioDynamics  (NAS:ANGO) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, AngioDynamics's WACC % is 6.48%. AngioDynamics's ROIC % is -8.09% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


AngioDynamics ROIC % Related Terms

Thank you for viewing the detailed overview of AngioDynamics's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioDynamics (AngioDynamics) Business Description

Traded in Other Exchanges
Address
14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.
Executives
Lorinda Burgess director 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff director C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea officer: SVP/GM, VIT C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel officer: SVP Global Operations and R&D 400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini officer: SVP International C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge officer: SVP and General Counsel 14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer director, officer: President and CEO COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson director
Chad Thomas Campbell officer: SVP/GM, Vascular Access 140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan officer: SVP Quality and Regulatory ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig officer: SVP and General Counsel C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould director 247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher officer: SVP and GM of Oncology 14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner officer: EVP and CFO C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421